Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: Relevance for its mode of action in Alzheimer's disease and geriatric depression

Molecular Psychiatry

Volumn 5, Issue 6, 2000, Pages 616-632

  Pettegrew, J W ^a   Levine, J ^a,b   McClure, R J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Acetyl L carnitine; Acetylation; Alzheimer's disease; Energy metabolism; Geriatric depression; Lipid metabolism; Membrane

Indexed keywords

ACETYL COENZYME A; CARNITINE; LEVACECARNINE; NEUROHORMONE; NEUROTROPHIC FACTOR; PHOSPHOLIPID;

ACETYLATION; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ARTICLE; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; DEPRESSION; ENERGY METABOLISM; FATTY ACID OXIDATION; GERIATRIC PATIENT; HUMAN; MOLECULAR DYNAMICS; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION;

EID: 0033653231     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000805     Document Type: Article

References (203)

1. The distribution of carnitine, acetylcarnitine, and carnitine acetyltransferase in rat tissues
2. Carnitine
3. Action of carnitine on long chain fatty acid oxidation by liver
4. Effects of carnitine on acetyl-CoA oxidation by heart muscle mitochondria
5. The metabolism of fatty acid esters of carnitine by mitochondria
6. Relationship between SPECT and pathological alterations in Alzheimer's disease - A study of a case with left-hemisphere dominant lesions
7. Biosynthesis and turnover of carnitine acetyltransferase in rat liver
8. Carnitine
9. Carnitine acetyltransferase: The question of multiple forms
10. Metabolism and disposition of intravenously administered acetyl-L-carnitine in healthy volunteers
11. Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type
12. Homeostatic equilibrium of L-carnitine family before and after i.v. administration of propionyl-L-carnitine in humans, dogs and rats
13. 11C]acetyl-L-carnitine into the brain: A PET study
14. Acetyl-L- carnitine modulates glucose metabolism and stimulates glycogen synthesis in rat brain
15. Carnitines increase plasma levels of adenosine and ATP in humans
16. Progressive decrease of cerebral cytochrome C oxidase activity in sparse-fur mice: Role of acetyl-L-carnitine in restoring the ammonia-induced cerebral energy depletion
17. Prevention of postischemic canine neurological injury through potentiation of brain energy metabolism by acetyl-L-carnitine
18. Acetylcarnitine and spermatozoa: Relationship with epididymal maturation and motility in the boar and man
19. Purinoceptors in the nervous system
20. Neuroprotective role of adenosine in cerebral ischaemia
21. Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport
22. Adenosine modulates hypoxia-induced responses in rat PC12 cells via the A2A receptor
23. The physiological role of carnitine
24. Enhancement of mitochondrial carnitine and carnitine acylcarnitine translocase-mediated transport of fatty acids into liver mitochondria under ketogenic conditions
25. Action of L-acetylcarnitine on age-dependent modifications of mitochondrial membrane proteins from rat cerebellum
26. 1H NMR spectroscopy
27. Acetyl-Lcarnitine influences the fluidity of brain microsomes and of liposomes made of rat brain microsomal lipid extracts
28. Acetylcarnitine increases membrane cytoskeletal protein-protein interactions
29. Effect of L-carnitine and acetyl-L-carnitine on the human erythrocyte membrane stability and deformability
30. The effect of aging and acetyl-L-carnitine on the activity of the phosphate carrier and on the phospholipid composition in rat heart mitochondria
31. Equilibrium constants of the reactions of choline acetyltransferase, carnitine acetyltransferase, and acetylcholinesterase under physiological conditions
32. The equilibrium constants of the adenosine triphosphate hydrolysis and the adenosine triphosphate-citrate lyase reactions
33. Carnitine acetyltransferase: A review of its biology, enzymology, and bioorganic chemistry
34. Comparison of the conformation of amyloid beta (1-28) peptide fragment with its Lys28 N-acetyl derivative
35. Acetyl-L-carnitine is involved in protein acetylation
36. Acetyl-L-carnitine decreases glycation of lens proteins: In vitro studies
37. Role of electrostatic interactions in the reaction of NADPH-cytochrome P-450 reductase with cytochromes P-450
38. Role of lysine and arginine residues of cytochrome P450 in the interaction between cytochrome P4502B1 and NADPH-cytochrome P450 reductase
39. 5 at 2.0 Angstrom resolution
40. Nerve growth factor binding in aged rat central nervous system: Effect of acetyl-L-carnitine
41. Effect of acetyl-L-carnitine on forebrain cholinergic neurons of developing rats
42. Acetyl-L-carnitine enhances the response of PC12 cells to nerve growth factor
43. Stimulation of nerve growth factor receptors in PC12 by acetyl-L-carnitine
44. Neurite outgrowth in PC12 cells stimulated by acetyl-L-carnitine arginine amide
45. Acetyl-L-carnitine treatment increases nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats
46. Acetyl-L-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fimbria-fornix transection
47. Spatial memory and NGF levels in aged rats: Natural variability and effects of acetyl-L-carnitine treatment
48. New protein fold revealed by a 2.3-A resolution structure of nerve growth factor
49. Inhibition of postcardiac arrest brain protein oxidation by acetyl-L-carnitine
50. Action of L-acetylcarnitine on different cerebral mitochondrial populations from cerebral cortex
51. Acetylcholinesterase activity of synaptic plasma membranes during ageing: Effect of L-acetylcarnitine
52. Brain enzyme activities after intracerebroventricular injection of streptozotocin in rats receiving acetyl-L-carnitine
53. Protein kinase C activation and anti-amnesic effect of acetyl-L-carnitine: In vitro and in vivo studies
54. Effect of acetyl-L-carnitine treatment on brain adenylate cyclase activity in young and aged rats
55. Action of L-acetylcarnitine on different cerebral mitochondrial populations from hippocampus and striatum during aging
56. 1.9-Å structures of ternary complexes of citrate synthase with D- and L-malate: Mechanistic implications
57. Electron transfer between cytochrome c and the isolated CuA domain: Identification of substrate-binding residues in cytochrome c oxidase
58. Atomic structure of acetylcholinesterase from Torpedo californica: A prototypic acetylcholine-binding protein
59. Sequence analysis of a proteolyzed site in Drosophila choline acetyltransferase
60. 2+
61. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha
62. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
63. Central cholinergic effects of levo-acetylcarnitine
64. Hypothalamo-pituitary-adenocortical function in aging: Effects of acetyl-L-carnitine
65. Acetyl-L-carnitine, adrenocortical hyperactivity and pathological aging brain
66. Effect of long-term acetyl-L-carnitine on stress-induced analgesia in the aging rat
67. Acetyl-L-carnitine as a modulator of the neuro-endocrine-immune interaction in HIV + subjects
68. In vivo and in vitro studies on modulation of the pineal endocrine function by L-acetyl-carnitine in the rat
69. Modulation of melatonin secretion by acetyl-L-carnitine in adult and old rats
70. Stimulation of gonadotropin-releasing hormone secretion by acetyl-L-carnitine in hypothalamic neurons and GT1 neuronal cells
71. Effect of different chronic intermittent stressors and acetyl-L-carnitine on hypothalamic beta-endorphin and GnRH and on plasma testosterone levels in male rats
72. Actions of acetyl-L-carnitine on the hypothalamo-pituitary-gonadal system in female rats
73. Acetyl-L-carnitine has a neuromodulatory influence on neuronal phenotypes during early embryogenesis in the chick embryo
74. Butyrate and acetyl-carnitine inhibit the cytogenetic expression of the fragile X in vitro
75. Ultrastructural aspects of aging rat hippocampus after long-term administration of acetyl-L-carnitine
76. Dynamic morphology of the synoptic junctional areas during aging: The effect of chronic acetyl-L-carnitine administration
77. Acetylcarnitine modulation of the morphology of rat hippocampal synapses
78. Effect of aging and acetyl-L-carnitine on energetic and cholinergic metabolism in rat brain regions
79. Acetyl-L-carnitine: Behavioral, electrophysiological, and neurochemical effects
80. Effect of the chronic treatment with L-acetylcarnitine in Down's syndrome
81. Developmental deficiency of the cholinergic system in congenitally hyperammonemic spf mice: Effect of acetyl-L-carnitine
82. Acetyl-L-carnitine restores choline acetyltransferase activity in the hippocampus of rats with partial unilateral fimbria-fornix transection
83. Spatial discrimination learning and choline acetyltransferase activity in streptozotocin-treated rats: Effects of chronic treatment with acetyl-L-carnitine
84. Acetyl-L-carnitine affects aged brain receptorial system in rodents
85. A cluster analysis study of acetyl-L-carnitine effect on NMDA receptors in aging
86. Acetyl-L-carnitine release, dopamine in rat corpus striatum: An in vivo microdialysis study
87. Acetyl-L-carnitine enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats
88. Effect of acetyl-L-carnitine on the dopaminergic system in aging brain
89. Activity of L-carnitine and L-acetylcarnitine on cholinoceptive neocortical neurons of the rat in vivo
90. Systemic acetyl-L-carnitine elevates nigral levels of glutathione and GABA
91. Stereospecific effects of acetylcarnitine on the spontaneous activity of brain-stem neurons and their responses to acetylcholine and serotonin
92. Effect of acetyl-L-carnitine on extracellular amino acid levels in vivo in rat brain regions
93. Alterations of the thalamo-cortical system in rats prenatally exposed to ethanol are prevented by concurrent administration of acetyl-L-carnitine
94. Effect of intraventricular injection of 1-methyl-4-phenylpyridinium: Protection by acetyl-L-carnitine
95. Neuroprotective activity of acetyl-L-carnitine: Studies in vitro
96. Activation of apoptosis by serum deprivation in a teratocarcinoma cell line: Inhibition by L-acetylcarnitine
97. Effect of acetyl-L-carnitine on hyperactivity and spatial memory deficits of rats exposed to neonatal anoxia
98. Acetyl-L-carnitine: Chronic treatment improves spatial acquisition in a new environment in aged rats
99. Long-term acetyl-L-carnitine treatment in Alzheimer's disease
100. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease
101. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease
102. Acetyl-L-carnitine slows decline in younger patients with Alzheimer s disease: A reanalysis of a double-blind, placebo-controlled study using the trilinear approach
103. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
104. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: Double blind trial
105. Cholinesterase inhibition for Alzheimer disease: A meta-analysis of the tacrine trials
106. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
107. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
108. Efficacy of donepezil in Alzheimer's disease: Fact or artifact?
109. Commentary: Another piece of the Alzheimer's jigsaw
110. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease
111. Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease
112. 31P NMR spectroscopy detects altered phospholipid metabolism in Alzheimer's disease
113. Evidence for a membrane defect in Alzheimer disease brain
114. 31P nuclear magnetic resonance studies of phosphoglyceride metabolism in developing and degenerating brain: Preliminary observations
115. P-31 NMR changes in Alzheimer's and Huntington's disease brain
116. 31P nuclear magnetic resonance study of the brain in Alzheimer's disease
117. Alterations of cerebral metabolism in probable Alzheimer's disease; a preliminary study
118. 31P magnetic resonance spectroscopy in Alzheimer's and Pick's disease
119. Phospholipid abnormalities in early Alzheimer's disease
120. Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia
121. Synaptic pathology of Alzheimer's disease
122. Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration
123. Synapse alterations in the hippocampal-entorhinal formation in Alzheimer's disease with and without Lewy body disease
124. Reduced O-glycosylated clathrin assembly protein AP180: Implication for synaptic vesicle recycling dysfunction in Alzheimer's disease
125. Neurochemical dissection of synaptic pathology in Alzheimer's disease
126. Biological markers in Alzheimer disease
127. Experimental therapeutics
128. Anatomic and functional brain imaging in Alzheimer's disease
129. Brain energy metabolizing enzymes in Alzheimer's disease: Alpha-ketoglutarate dehydrogenase complex and cytochrome oxidase
130. Brain energy metabolism, cognitive function and down-regulated oxidative phosphorylation in Alzheimer disease
131. Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer's disease
132. Altered glucose metabolism in microvessels from patients with Alzheimer's disease
133. Action mechanism of antidepressants
134. Second messenger-regulated protein kinases in the brain: Their functional role and the action of antidepressant drugs
135. Membrane transport processes in affective illness
136. Membrane biophysical studies of lymphocytes and erythrocytes in manic-depressive illness
137. Sodium-23 NMR analysis of human whole blood, erythrocyte and plasma. Chemical shift, spin relaxation and intracellular sodium concentration studies
138. Toward a molecular basis for affective disorders
139. 7Li study of normal human erythrocytes
140. The effect of lithium on the membrane molecular dynamics of normal human erythrocytes
141. 2 a predisposing factor in affective illness
142. Alterations in membrane molecular dynamics in erythrocytes of patients with affective illness
143. Lipid polymorphism and the functional roles of lipids in biological membranes
144. The molecular organization of the red cell membrane skeleton
145. Interactions between components in biological membranes and their implications for membrane function
146. A rapid method of reconstituting human erythrocyte sugar transport proteins
147. Effects of biolayer cholesterol of human erythrocyte hexose transport protein activity in synthetic lecithin bilayers
148. ESR study of the erythrocyte membrane skeletal protein network: Influence of the state of aggregation of spectrin on the physical state of membrane proteins, bilayer lipids, and cell surface carbohydrates
149. The lipid structure of biological membranes
150. How bilayer lipids affect membrane protein activity
151. Regulation of membrane fusion in secretory exocytosis
152. Correlation between acetylcholine receptor function and structural properties of membranes
153. Polymorphic regulation of membrane lipid composition
154. Return of the magnificient seven
155. Three of a kind: The b-adrenergic receptor, the muscarinic acetylcholine receptor, the rhodopsin
156. Interaction of the cytoskeleton framework with acetylcholine receptors on the surface of embryonic muscle cells in culture
157. Association of the postsynaptic 43K protein with newly formed acetylcholine receptor clusters in cultured muscle cells
158. The role of the postsynaptic cytoskeleton in AChR organization
159. Quick-freeze, deep-etch visualization of the axonal cytoskeleton
160. Formation and dispersal of acetylcholine receptor clusters in muscle cells
161. Electrostatic coupling of spectrin dimers to phosphatidylserine containing lipid lamellae
162. +) ATPase and implications for the organization of membrane domains in polarized cells
163. Plasma cholesterol and depressive symptoms in older men
164. Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: Relationship with immune-inflammatory markers
165. Depressive symptoms, social support, and lipid profile in healthy middleaged women
166. Low cholesterol concentrations and severe depressive symptoms in elderly people
167. Serum lipid concentrations in patients with major depressive disorder
168. Effects of dexamethasone on the availability of L-tryptophan and on the insulin and FFA concentrations in unipolar depressed patients
169. Fatty acid composition in major depression: Decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids
170. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients
171. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients
172. Increased sensitivity of the inositol-phospholipid system in neutrophils from patients with acute major depressive episodes
173. Abnormalities of one-carbon metabolism in psychiatric disorders: Study of methionine adenosyltransferase kinetics and lipid composition of erythrocyte membranes
174. L-Acetyl carnitine in depressed elderly subjects. A cross-over study vs placebo
175. Acetyl-L-carnitine in depressed geriatric patients
176. Amelioration of the depression of HIV-infected subjects with L-acetyl carnitine therapy
177. Action of acetyl-L-carnitine in association with mianserine on depressed old people
178. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders
179. Laevo-acetylcarnitine (Nicetile(R)) treatment of senile depression
180. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression
181. Acetyl-L-carnitine in aged subjects with major depression: Clinical efficacy and effects on the circadian rhythm of cortisol
182. Treatment outcome in recurrent major depression: A posthoc comparison of elderly ('young old') and mid-life patients
183. Predicting response to fluoxetine in geriatric patients with major depression
184. Double-blind, controlled trial of inositol treatment of depression
185. Omega 3 fatty acids in bipolar disorder: A preliminary double-blind, placebo-controlled trial
186. The effect of myo-inositol deficiency on lipid metabolism in rats. II. The mechanism of triacylglycerol accumulation in the liver of myo-inositol-deficient rats
187. Chronic myo-inositol increases rat brain phosphatidylethanolamine plasmalogen
188. Plasmenylethanolamine facilitates rapid membrane fusion: A stopped-flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt an HII phase with its ability to promote membrane fusion
189. Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats
190. Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na,K- ATPase activity, and motor conduction velocity in the streptozotocin-diabetic rat
191. 31P NMR spectra of cats receiving lithium chloride systemically
192. Systemic lithium administration alters rat cerebral cortex phospholipids
193. Effects of lithium treatment in vitro and in vivo on acetylcholine metabolism in rat brain
194. Evidence that lithium alters phosphoinositide metabolism: Chronic administration elevates primarily D-myo-inositol-1-phosphate in cerebral cortex of the rat
195. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands
196. Effect of aging and acetyl-L-carnitine on energetic and cholinergic metabolism in rat brain regions
197. Acetyl-L-carnitine: Behavioral, electrophysiological, and neurochemical effects
198. Chronic lithium treatment decreases brain phospholipase A2 activity
199. Lithium's effects on cyclic AMP, membrane transport and cholinergic mechanisms
200. Lithium and cyclic AMP
201. Lithium inhibits adrenergic and cholinergic increased in GTP binding in rat cortex
202. Lithium stimulation of membrane-bound phospholipase C from C12 cells exposed to nerve growth factor